Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2025)

BridgeBio Pharma's Change in Receivables history spans 2 years, with the latest figure at $22.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 440.2% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $134.7 million, up 4434.57%, while the annual FY2025 figure was $134.7 million, 4434.57% up from the prior year.
  • Change in Receivables for Q4 2025 was $22.9 million at BridgeBio Pharma, down from $39.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $233.7 million in Q1 2024 and bottomed at -$234.8 million in Q2 2024.